Wren Laboratories

Wren Laboratories is revolutionizing cancer diagnostics with advanced machine learning and liquid biopsy mRNA-based technology. Our goal is to provide precise, non-invasive diagnostics tailored to each patients unique molecular profile, transforming early detection and surveillance of cancer for better patient outcomes. With over 100 patents and validation from more than 60 clinical studies, Wren has developed highly sensitive liquid biopsy mRNA gene expression-based assays. These innovative assays aid in cancer diagnosis, detect minimal residual disease (MRD), and predict tumor prognosis and therapeutic response. Our tests, including the NETest for neuroendocrine tumors and PROSTest for prostate cancer, leverage mRNA technology and...

Neuroendocrine tumors,cancer,diagnosis,prostate cancer,breast cancer,lung cancer,ai,liquid biopsy,biomarkers,molecular diagnostics,personalized medicine,minimal residual disease,myeloma,colorectal cancer,pancreatic cancer,machine learning,and companion diagnostics

Wren laboratories operates in the Biotechnology research industry.

Wren laboratories's revenue is 11m - 100m

Wren laboratories has 11 - 50 employees.